| DC72592 |
Zelasudil
|
Zelasudil is a Rho-associated coiled-coil kinase (ROCK) inhibitor with a specific binding affinity for ROCK2, a key enzyme in the Rho/ROCK signaling pathway. This pathway plays a critical role in regulating cellular processes such as cytoskeletal organization, cell motility, smooth muscle contraction, and gene expression. By selectively inhibiting ROCK2, Zelasudil modulates these processes, offering therapeutic potential for a variety of diseases characterized by fibrosis, inflammation, and vascular dysfunction, including pulmonary fibrosis, glaucoma, and cardiovascular diseases. |
| DC45762 |
Y-27632
|
Y-27632 is a selective ROCK1 (p160ROCK) inhibitor with Ki of 140 nM in a cell-free assay, exhibits >200-fold selectivity over other kinases, including PKC, cAMP-dependent protein kinase, MLCK and PAK. |
| DC10167 |
ZINC00881524
|
ZINC00881524 is a ROCK inhibitor. |
| DC8567 |
3-(4-Pyridyl)
|
3-(4-Pyridyl)indole is a ROCK-I inhibitor (IC50 = 25 µM) that promotes cell spreading, inhibits membrane blebbing, and induces dissolution of actin stress fibers in a wound healing assay |
| DC81490 |
SAR113945
|
SAR113945 (compound 1) is a highly potent IKK-β inhibitor with an IC50 of 0.4 nM. SAR113945 is used for research on inflammatory and cancerous diseases. |
| DC80433 |
CHNQD-01522
|
CHNQD-01522 is a microtubule inhibitor targeting the colchicine binding site on β-tubulin. CHNQD-01522 binds to the colchicine binding site on β-tubulin, inhibits microtubule polymerization, and evades P-glycoprotein transport in cancer cells. CHNQD-01522 inhibits proliferation, suppresses tumor cell colony formation, arrests cell cycle in G2/M phases, and induces apoptosis in cancer cells. CHNQD-01522 upregulates of Bax and activation of caspase-9 and caspase-3. CHNQD-01522 shows anti-tumor efficacy in subcutaneous and orthotopic hepatocellular carcinoma xenograft tumor models. CHNQD-01522 can be used for the research of hepatocellular carcinoma. |
| DC80344 |
Briciclib sodium
|
Briciclib (ON 014185) sodium is a eukaryotic translation initiation factor 4E (eIF4E) inhibitor. Briciclib sodium exhibits broad-spectrum anti-cancer activity, including in mantle cell leukemia, breast cancer, gastric cancer, and esophageal cancer cells. Briciclib sodium reduces the expression of cyclin D1 and c-Myc, and enhances the expression of P53 and Cleaved Caspase 3 pro-apoptotic proteins. Briciclib sodium can be used for the study of hematological system tumors and solid tumors. |
| DC80140 |
ABC transporter
modulator-2
|
ABC transporter modulator-2 (Compound I-200) is a ABC transporter expression modulator. ABC transporter modulator-2 upregulates the expression of wild-type ABCC6 with an EC50 of <1 μM. ABC transporter modulator-2 upregulates the expression of wild-type ABCB4 with an EC50 of <1 μM. ABC transporter modulator-2 upregulates the expression of wild-type ABCD2 with an EC50 of <1 μM. ABC transporter modulator-2 upregulates the expression of the ABCA4P1380L mutant with an EC50 of <1 μM. ABC transporter modulator-2 can be used in the research of diseases associated with ABC transporter dysfunction. |
| DC79196 |
Desisopropyle-belumosudil
|
KD025m1 is a novel selective ROCK2 inhibitor. KD025m1 has good anti obesity, improved insulin sensitivity, and blood glucose control effects. KD025m1 can be used to study metabolic diseases such as diabetes and obesity. |
| DC73226 |
Netarsudil
|
Netarsudil (AR-13324) is a potent, selective ROCK inhibitor with Ki of 4.2 nM for ROCK2. |
To enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
